Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Recruiting now

Conditions studied: Neuroendocrine Tumors, Neuroendocrine Neoplasm, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Carcinoma

In brief

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

Key facts

Study ID

NCT04464122

Run by

University of Roma La Sapienza

People needed

60

Starts

2020-09-14

Expected to finish

2025-12-31

Last updated by the study team

2025-04-03

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically-proven NENs, locally advanced or metastatic, originating from pulmonary or gastro-entero-pancreatic (GEP) tract, candidate to first line medical therapy (study group);
• Patients affected by other non-malignant endocrine disease, e.g. benign thyroid disfunction (control group).

You may not qualify if…

• Severe chronic kidney disease (stage 4-5);
• Clinical or laboratory signs of significant respiratory, cardiological and hepatobiliary disease;
• Other non-neuroendocrine malignancies.

Where it is running

• Andrea M Isidori — Rome, Italy, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.